O'Halloran Charlotte, Cullen Katelyn, Njoroge Jaquelyn, Jessop Lucy, Smith Josie, Hope Vivian, Ncube Fortune
HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Int J Drug Policy. 2017 Aug;46:34-40. doi: 10.1016/j.drugpo.2017.05.017. Epub 2017 Jun 3.
Overdose is a major cause of death among PWID, and for opioid overdoses naloxone administration can reduce harm. However, globally there is limited national level data on the extent of non-fatal overdose and naloxone uptake. The first national level data on the extent of self-reported overdose and self-reported receipt of naloxone among UK PWID, providing a baseline to monitor the impact of the recent policy change regarding naloxone availability, is presented.
Data on self-reported overdose and receipt of naloxone during the preceding year for 2013-2014 from a national survey of PWID was analysed. Participants who reported injecting during the preceding year were included.
Participants (3850) were predominantly male (75%); mean age was 36 years. The most commonly injected drugs were: heroin (91%), crack (45%) and amphetamine (29%). 15% (591) reported overdosing during the preceding year. There were no differences in the proportion reporting overdose by age or gender, but overdose was more common among those who: injected multiple drugs; recently ceased addiction treatment; injected with used needles/syringes; ever had transactional sex; had used a sexual health clinic or emergency department and lived in Wales or Northern Ireland. Among those reporting an overdose during the preceding year, a third reported two to four overdoses and 7.5% five or more overdoses; half reported receiving naloxone. Those reporting naloxone receipt in the preceding year were more likely to: live in Wales or Northern Ireland; ever received used needles/syringes; ever been imprisoned; and less likely to have injected two drug types.
These data provide a baseline for monitoring the impact of the 2015 UK policy change to improve take-home naloxone access. Interventions tackling overdose should promote naloxone awareness and access, and target those who; are poly-drug injectors, have ceased treatment, share needles/syringes and whose drug use links to sexual activity.
过量用药是注射吸毒者死亡的主要原因,对于阿片类药物过量,注射纳洛酮可减少伤害。然而,全球范围内关于非致命过量用药程度和纳洛酮使用情况的国家级数据有限。本文呈现了英国注射吸毒者中自我报告的过量用药程度和纳洛酮使用情况的首批国家级数据,为监测近期纳洛酮供应政策变化的影响提供了基线。
分析了2013 - 2014年对注射吸毒者进行的全国性调查中关于前一年自我报告的过量用药和纳洛酮使用情况的数据。纳入了前一年报告有注射行为的参与者。
参与者(3850人)以男性为主(75%);平均年龄为36岁。最常注射的毒品是:海洛因(91%)、快克(45%)和苯丙胺(29%)。15%(591人)报告在前一年有过量用药情况。报告过量用药的比例在年龄或性别上没有差异,但在以下人群中过量用药更为常见:注射多种毒品者;最近停止戒毒治疗者;使用用过的针头/注射器注射者;有过交易性行为者;去过性健康诊所或急诊科者以及居住在威尔士或北爱尔兰者。在前一年报告有过量用药的人群中,三分之一报告有两到四次过量用药,7.5%报告有五次或更多次过量用药;一半报告接受过纳洛酮。在前一年报告接受过纳洛酮的人群更有可能:居住在威尔士或北爱尔兰;曾接受用过的针头/注射器;曾被监禁;且注射两种毒品类型的可能性较小。
这些数据为监测2015年英国改善纳洛酮带回家使用政策变化的影响提供了基线。应对过量用药的干预措施应提高纳洛酮的知晓度和可及性,并针对以下人群:多药注射者、已停止治疗者、共用针头/注射器者以及其吸毒与性活动有关者。